Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

EVP, Corp and Development Ops

EVP, Chief Business Officer

Officer Level 14

Vice President Level 14

CEO Level 15

Chief Executive Officer

EVP, Finance & CFO

EVP, Chf GL Pdt Str & Oper Ofc

EVP, Chief Scientific Officer

EVP, Chief Development Officer

EVP CLO & General Counsel

EVP, Chf Clinical Develop Ofcr

EVP Research

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-05-03	Premium	sold	Premium	Premium	Premium	-
2024-04-16	Premium	sold	Premium	Premium	Premium	EVP, Corp and Development Ops
2024-04-16	Premium	sold	Premium	Premium	Premium	EVP, Chief Business Officer
2024-04-15	Premium	acquired	Premium	Premium	Premium	EVP, Chief Business Officer
2024-04-15	Premium	acquired	Premium	Premium	Premium	EVP, Corp and Development Ops
2024-02-29	Premium	acquired	Premium	Premium	Premium	Officer Level 14
2024-02-29	Premium	acquired	Premium	Premium	Premium	Officer Level 14
2024-02-29	Premium	acquired	Premium	Premium	Premium	Officer Level 14
2024-02-29	Premium	acquired	Premium	Premium	Premium	Vice President Level 14
2024-02-29	Premium	acquired	Premium	Premium	Premium	CEO Level 15
2024-02-16	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-02-02	Premium	sold	Premium	Premium	Premium	EVP, Finance & CFO
2024-02-02	Premium	sold	Premium	Premium	Premium	EVP, Chf GL Pdt Str & Oper Ofc
2024-02-02	Premium	sold	Premium	Premium	Premium	EVP, Chief Scientific Officer
2024-02-02	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-02-02	Premium	sold	Premium	Premium	Premium	EVP, Chief Development Officer
2024-02-02	Premium	sold	Premium	Premium	Premium	EVP CLO & General Counsel
2024-02-02	Premium	sold	Premium	Premium	Premium	EVP, Chf Clinical Develop Ofcr
2024-02-02	Premium	sold	Premium	Premium	Premium	EVP Research
2024-02-01	Premium	acquired	Premium	Premium	Premium	EVP Research
2024-02-01	Premium	acquired	Premium	Premium	Premium	EVP, Chief Scientific Officer
2024-02-01	Premium	acquired	Premium	Premium	Premium	EVP, Finance & CFO
2024-02-01	Premium	acquired	Premium	Premium	Premium	EVP, Chf GL Pdt Str & Oper Ofc
2024-02-01	Premium	acquired	Premium	Premium	Premium	EVP CLO & General Counsel
2024-02-01	Premium	acquired	Premium	Premium	Premium	EVP, Chief Development Officer

IONS - Ionis Pharmaceuticals Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for IONS